Novo Nordisk's stock price experienced a significant drop on Tuesday following the announcement of a new CEO and a downward revision of its full-year sales and profit forecasts. The Danish pharmaceutical company, known for its popular weight-loss drug Wegovy, cited unforeseen challenges as the reason for the adjusted financial outlook. Investors reacted negatively to the news, reflecting concerns about the company's near-term performance and future growth trajectory under new leadership. The revised guidance has raised questions about the sustainability of Novo Nordisk's recent success and its ability to maintain its market position in the competitive pharmaceutical landscape.